Search

Your search keyword '"Maurizio Gabrielli"' showing total 4 results
Start Over Author "Maurizio Gabrielli" Journal alimentary pharmacology & therapeutics
4 results on '"Maurizio Gabrielli"'

1. Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19

Author

Lorenzo Maria Vetrone, Luisa Sestito, Angelo Porfidia, Alessandro BUONOMO, Antonio Gasbarrini, Rosario Landi, Laura Franza, Maurizio Sanguinetti, Francesco Antonio Mancarella, Riccardo Inchingolo, Silvia Bosello, Andrea Corsello, Francesca Ciciarello, Caterina Guidone, Vincenzo Bove, Martina De Siena, Carlo Romano Settanni, Luca Miele, Mattia Paratore, Raffaele Iorio, Gianluca Ianiro, Cristiano Caruso, Elisabetta Nardella, Alfredo PAPA, Stefano Bibbò, Maurizio Gabrielli, Simone Perniola, Angelo Carfì, Laura Gigante, Domenico Fusco, Valerio Pontecorvi, Paolo Santini, Antonella Giampietro, Impagnatiello Michele, Gabriele Pulcini, Giovanni Cammarota, Serena PORCARI, Massimo FANTONI, Federico Biscetti, Francesco De Vito, Dario Bruno, Luca Petricca, LUCREZIA VERARDI, Jacopo Simonetti, Tommaso Schepis, Tommaso Nicoletti, Elisa Gremese, Francesco Lombardi, Leonardo Stella, Gerlando Natalello, Flavio De Maio, Giuseppe Parrinello, and Gabriele Rumi

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Hepatology, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Settore MED/09 - MEDICINA INTERNA, Gastroenterology, MEDLINE, Letter to the Editors, Letters to the Editors, 03 medical and health sciences, 0302 clinical medicine, covid-19, Internal medicine, Cohort, medicine, 030211 gastroenterology & hepatology, Pharmacology (medical), 030212 general & internal medicine, business
Abstract

LINKED CONTENT This article is linked to Tian et al and Tian and Rong papers. To view these articles, visit https://doi.org/10.1111/apt.15731 and https://doi.org/10.1111/apt.15986

Published
2020

2. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth

Author

C. Lauritano, Maurizio Gabrielli, Giovanni Cammarota, Antonio Gasbarrini, Emidio Scarpellini, Giovanni Gasbarrini, Andrea Lupascu, Immacolata A. Cazzato, and Giuseppe Merra

Subjects
Breath test, medicine.medical_specialty, Intention-to-treat analysis, Hepatology, medicine.diagnostic_test, medicine.drug_class, business.industry, Incidence (epidemiology), Antibiotics, Gastroenterology, medicine.disease, Surgery, Rifaximin, chemistry.chemical_compound, chemistry, Tolerability, Internal medicine, Small intestinal bacterial overgrowth, medicine, Pharmacology (medical), business, Antibacterial agent
Abstract

ummary Background Rifaximin is a broad spectrum non-absorbable antibiotic used for treatment of small intestinal bacterial overgrowth. Doses of 1200 mg/day showed a decontamination rate of 60% with low side-effects incidence. Aims To assess efficacy, safety and tolerability of rifaximin 1600 mg with respect to 1200 mg/day for small intestinal bacterial overgrowth treatment. Methods Eighty consecutive small intestinal bacterial overgrowth patients were enrolled. Diagnosis of small intestinal bacterial overgrowth based the clinical history and positivity to H2/CH4 glucose breath test. Patients were randomized in two 7-day treatment groups: rifaximin 1600 mg (group 1); rifaximin 1200 mg (group 2). Glucose breath test was reassessed 1 month after. Compliance and side-effect incidence were also evaluated. Results One drop-out was observed in group 1 and two in group 2. Glucose breath test normalization rate was significantly higher in group 1 with respect to group 2 both in intention-to-treat (80% vs. 58%; P

Published
2007

3. Atrophic gastritis as a cause of hyperhomocysteinaemia

Author

Marcello Candelli, Giovanni Gasbarrini, Maurizio Gabrielli, Angelo Santoliquido, Paolo Pola, Filippo Cremonini, Enrico Celestino Nista, Antonio Gasbarrini, and Luca Santarelli

Subjects
Vitamin, Hyperhomocysteinemia, medicine.medical_specialty, Malabsorption, Hepatology, biology, Atrophic gastritis, business.industry, Gastroenterology, Odds ratio, Helicobacter pylori, medicine.disease, biology.organism_classification, chemistry.chemical_compound, chemistry, Internal medicine, medicine, Pharmacology (medical), Vitamin B12, Gastritis, medicine.symptom, business
Abstract

Summary Background : Hyperhomocysteinaemia is an independent risk factor for atherosclerosis. It is often related to low levels of vitamin B12 and/or folate, enzymatic co-factors of methionine metabolism. Atrophic gastritis, often caused by Helicobacter pylori infection, may impair vitamin absorption. Aim : To assess whether the presence of atrophic gastritis is associated with hyperhomocysteinaemia via deficiency of its vitamin co-factors. Methods : Thirty-one patients with atrophic gastritis were recruited. The control group consisted of 28 patients with non-atrophic gastritis, matched with patients for sex, age and body mass index. The presence and degree of gastric atrophy were assessed by histology. H. pylori infection was assessed by histology/serology. Blood samples were collected for the measurement of homocysteine, vitamin B12 and folates. Results : Multiple logistic regression analysis showed that atrophic gastritis (odds ratio, 5.3; 95% confidence interval, 1.23–25.26; χ2 = 5.2; P = 0.01) and low vitamin B12 (odds ratio, 3.7; 95% confidence interval, 1.03–22.08; χ2 = 3.6; P

Published
2003

4. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture

Author

Veronica Ojetti, Maurizio Gabrielli, Emidio Scarpellini, Annalisa Tortora, Flaminia Purchiaroni, and Antonio Gasbarrini

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, MEDLINE, medicine.disease, Internal medicine, Predictive value of tests, Small intestinal bacterial overgrowth, medicine, Pharmacology (medical), business, Irritable bowel syndrome
Published
2011

Catalog

Books, media, physical & digital resources
See catalog results